Epidermicin NI01, a First-in-Class Peptide Antibiotic Candidate, Has Potent Efficacy in a Robust MRSA Wound Infection Model and Low Allergic Reaction Liabilities
Over 10% of antibiotic prescriptions are for skin infections.1,2 New therapeutic approaches are required, and new modalities may be...
Epidermicin NI01, has been featured in EMJ Reviews following a presentation by CSO @matupton.bsky.social at @escmid.bsky.social Global 2025.
The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.
16.06.2025 10:59
๐ 2
๐ 2
๐ฌ 0
๐ 0
Thank you Paula - great to meet you & share the floor for the evening. Looking forwards to some new collaborations.
21.11.2024 21:17
๐ 1
๐ 0
๐ฌ 0
๐ 0